What’s Vericel Corporation (VCEL) Upside After Today’s Significant Increase?

March 14, 2018 - By reb123z

The stock of Vericel Corporation (NASDAQ:VCEL) is a huge mover today! The stock increased 2.64% or $0.3 during the last trading session, reaching $11.65. About 1.13M shares traded or 15.95% up from the average. Vericel Corporation (NASDAQ:VCEL) has declined 10.47% since March 14, 2017 and is downtrending. It has underperformed by 27.17% the S&P500.
The move comes after 5 months positive chart setup for the $406.68 million company. It was reported on Mar, 14 by Barchart.com. We have $12.00 PT which if reached, will make NASDAQ:VCEL worth $12.20M more.

Vericel Corporation (NASDAQ:VCEL) Ratings Coverage

Among 4 analysts covering Vericel (NASDAQ:VCEL), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Vericel had 12 analyst reports since March 11, 2016 according to SRatingsIntel. Piper Jaffray maintained the shares of VCEL in report on Tuesday, October 3 with “Buy” rating. The company was maintained on Monday, March 5 by BTIG Research. The firm has “Buy” rating by Piper Jaffray given on Wednesday, August 9. Piper Jaffray maintained Vericel Corporation (NASDAQ:VCEL) on Tuesday, January 2 with “Buy” rating. Needham maintained Vericel Corporation (NASDAQ:VCEL) on Wednesday, November 9 with “Buy” rating. The rating was maintained by BTIG Research with “Buy” on Tuesday, November 7. The firm has “Buy” rating by Needham given on Friday, March 11. The firm has “Neutral” rating given on Tuesday, April 5 by Bank of America. Piper Jaffray initiated Vericel Corporation (NASDAQ:VCEL) rating on Thursday, December 22. Piper Jaffray has “Overweight” rating and $6 target. The rating was maintained by BTIG Research with “Buy” on Wednesday, August 9.

More notable recent Vericel Corporation (NASDAQ:VCEL) news were published by: Globenewswire.com which released: “Vericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference” on February 26, 2018, also Nasdaq.com with their article: “Vericel Corp. (VCEL) Has Climbed To A New High Following Q4 Report” published on March 05, 2018, Globenewswire.com published: “World Champion Swimmer and Twelve-Time Medalist Dara Torres Partners with …” on March 05, 2018. More interesting news about Vericel Corporation (NASDAQ:VCEL) were released by: Globenewswire.com and their article: “Vericel to Present at the 17th Annual Needham Healthcare Conference” published on March 13, 2018 as well as Globenewswire.com‘s news article titled: “Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March …” with publication date: February 22, 2018.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $406.68 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: